RWD Patients With Pulmonary Arterial Hypertension Treated With IP Prostacyclin Receptor Agonists
NCT ID: NCT05600218
Last Updated: 2022-11-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
60 participants
OBSERVATIONAL
2021-06-01
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of this study answer the following questions:
* Changes in the mortality risk profile of these patients after treatment administration.
* Baseline characteristics of patients initiating Selexipag.
* Parameters used for risk stratification prior to treatment escalation.
* Events during follow-up.
No comparison group available
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension
NCT04175600
Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension
NCT02471183
Selonsertib in Adults With Pulmonary Arterial Hypertension
NCT02234141
A Study of Single and Multiple Doses of Different Formulations of a Prostacyclin Receptor Agonist
NCT05427162
A Study to Evaluate GSK1325760A - a Long-Term Extension Study
NCT00554619
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1
Patients with pulmonary arterial hypertension on treatment with prostacyclin IP receptor agonists because they are at intermediate risk of mortality at one year
No intervention - Observational study
Real life drug evaluation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention - Observational study
Real life drug evaluation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients living 6 months or less in the reference health area
* Patients with active malignant tumors
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital Universitario Virgen Macarena
OTHER
Hospital Regional de Malaga
OTHER
Hospital Universitario Virgen de la Victoria
OTHER
Hospital San Juan de la Cruz
OTHER
Complejo Hospitalario de Especialidades Juan Ramón Jimenez
OTHER
Hospitales Universitarios Virgen del Rocío
OTHER
Hospital Clinico Universitario San Cecilio
OTHER
Hospital Universitario de Valme
OTHER
Hospital de Poniente
UNKNOWN
Hospital Costa del Sol
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rafael Bravo Marqués
Medical Specialist, Department of Cardiology, Hospital Costa del Sol, Marbella (Malaga,) Spain
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital de Poniente
El Ejido, Almería, Spain
Hospital San Juan de la Cruz
Úbeda, Jaén, Spain
Hospital Costa del Sol
Marbella, Málaga, Spain
Hospital Clinico Universitario San Cecilio
Granada, , Spain
Hospital Juan Ramón Jiménez
Huelva, , Spain
Hospital Regional de Malaga
Málaga, , Spain
Hospital Universitario Virgen de la Victoria
Málaga, , Spain
Hospital Universitario de Valme
Seville, , Spain
Hospital Universitario Virgen del Rocío
Seville, , Spain
Hospital Universitario Virgen Macarena
Seville, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Joaquín Vizcaíno Ricoma
Role: primary
Bonilla Palomas Bonilla Palomas
Role: primary
Rafael Bravo Marques
Role: primary
Juan Luis Calleja Rubio
Role: primary
José Morgado García de Polavieja
Role: primary
Francisco Espíldora Hernández
Role: primary
Víctor Becerra Muñoz
Role: primary
Irene María Estrada Parra
Role: primary
Amadeo Wals Rodríguez
Role: primary
Alejandro Recio Mayoral
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0991-N-21
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.